key: cord-0822443-o6gfxqxr authors: Yılmaz, Kamil; Şen, Velat title: Is vitamin D deficiency a risk factor for COVID‐19 in children? date: 2020-10-13 journal: Pediatr Pulmonol DOI: 10.1002/ppul.25106 sha: cccced84dd24448ac48060442dd722bbe8ae33ba doc_id: 822443 cord_uid: o6gfxqxr OBJECTIVE: Coronavirus disease 2019 (COVID‐19) is a global health problem that can result in serious complications. The aim of this study was to investigate the prevalence and clinical importance of vitamin D deficiency in children with COVID‐19. MATERIAL AND METHODS: This study includes 40 patients who were diagnosed to have COVID‐19 and hospitalized with the real‐time reverse transcription polymerase chain reaction method, 45 healthy matched control subjects with vitamin D levels. The age of admission, clinical and laboratory data, and 25‐hydroxycholecalciferol (25‐OHD) levels were recorded. Those with vitamin D levels which are below 20 ng/ml were determined as Group 1 and those with ≥20 ng/ml as Group 2. RESULTS: Patients with COVID‐19 had significantly lower vitamin D levels 13.14 μg/L (4.19–69.28) than did the controls 34.81 (3.8–77.42) μg/L (p < .001). Patients with COVID‐19 also had significantly lower serum phosphorus (4.09 ± 0.73 vs. 5.06 ± 0.93 vs. (U/L) (p < .001)) values compared with the controls. The symptom of fever was significantly higher in COVID‐ 19 patients who had deficient and insufficient vitamin D levels than in patients who had sufficient vitamin D levels (p = .038). There was a negative correlation found between fever symptom and vitamin D level (r = −0.358, p = .023). CONCLUSION: This is the first to evaluate vitamin D levels and its relationship with clinical findings in pediatric patients with COVID‐19. Our results suggest that vitamin D values may be associated with the occurrence and management of the COVID‐19 disease by modulating the immunological mechanism to the virus in the pediatric population. estimated to have vitamin D deficiency. Vitamin D is a pluripotent hormone modulating the adaptive and innate immune response. 8 The risk of infection by several mechanisms can be reduced by vitamin D. Vitamin D induces cathelicidins and defensins that can reduce the viral replication rate. In addition, it increases the concentrations of anti-inflammatory cytokines and decreases the concentration of proinflammatory cytokines that cause pneumonia and lung damage. 1 In previous studies, vitamin D deficiency has been shown to increase respiratory infections risk including respiratory syncytial virus, tuberculosis and flu, and is a risk factor for acute respiratory distress syndrome (ARDS). 8 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus among the COVID-19 patients, enters host cells by binding to receptors of angiotensin-converting enzyme 2 (ACE2) in the respiratory tract of infected patients. 9 The primary targets of coronaviruses are Type-II pneumocytes and there is high expression of ACE2 receptors in these cells. The level of surfactant can be reduced due to dysfunction of Type-II pneumocytes, and this can lead to increased surface tension in COVID-19. 10 It has been shown that surfactant synthesis in alveolar Type-II cells is stimulated by 1,25dihydroxyvitamin D metabolites. 11 The vitamin D agonist calcitriol is thought to have protective effects against acute lung injury by modulating the expression of members of the renin-angiotensin system, such as ACE 2 in lung tissue. 12 This information suggests that vitamin D deficiency may have a potential role as a pathogenic factor in COVID-19. CD26 is a putative adhesion molecule for COVID-19 host cell invasion. Adjustment of vitamin D deficiency is thought to suppress CD26. Vitamin D may also reduce, interleukin-6 (IL-6) and interferon gamma (IFNγ) inflammatory reactions, both potent predictors of worse clinical outcome in severe Vitamin D is a secosteroid with a wide range of immunomodulatory, anti-inflammatory, antifibrotic and antioxidant effects. It is thought that inflammatory cytokine expression is inhibited by vitamin D and its deficiency is associated with overexpression of Th1 cytokines. 14 Epidemiological studies have reported an association between vitamin D deficiency and acute lung injury and viral respiratory infections. 15 A randomized trial from China reported the beneficial effects of vitamin D is appropriate for the prevention of seasonal influenza as proved by rapid relief from symptoms, fast reduce, in viral loads and disease recovery. 16 Another randomized trial of daily high dose versus standard dose of vitamin D in Canadian children showed that the incidence of influenza infections in the high-dose group was reduced by 50%. 17 The immune response against respiratory virus infections might be improved by a sufficient level of 25 (OH) D in serum. 18 In the face of the COVID-19 pandemic, and in the lack of a vaccine or any effective antiviral treatment, supplementation of vitamin D hospital inpatients might be beneficial. In this study, we aimed to determine the prevalence and clinical importance of vitamin D deficiency in children and adolescent patients who were hospitalized with the diagnosis of COVID-19. Endocrinology or Pediatric outpatient clinics and whose vitamin D level was checked. Cases with chronic diseases and co-morbidities, and those younger than 1 month and older than 18 were excluded from the patients group and control group. The data of the cases included in the study were obtained from retrospective file records. The age of admission, clinical and laboratory data, and 25-hydroxycholecalciferol (25-OHD) and parathormone (PTH) levels were recorded. 25-hydroxycholecalciferaol level was examined in Shimatzu device by high performance liquid chromatography method. PTH level was examined by electro chemiluminescence method in Siemens Advia Centaur device. Those with 25-OHD level less than 12 ng/ml were considered as vitamin D deficient, those between 12 and 20 ng/ml were considered vitamin D insufficient and those with greater than 20 ng/ml were considered to have a normal vitamin D. 19 Patients diagnosed with COVID-19 were divided into two groups. Those with vitamin D levels which are below 20 ng/ml were determined as Group 1 and those with ≥20 ng/ml as were considered statistically significant. The mean age and age ranges of the groups were as follows: Table 2 . The distribution of disease severity according to vitamin D levels was not found significantly different (Table 3) . There was a negative correlation found between fever symptom and vitamin D level (p = .023, Table 4 ). However, no significant correlations were found between other clinical parameters and vitamin D level (data were not shown). Our study evaluated the vitamin D deficiency prevalence and the asso- the community-acquired pneumonia group displayed a lower value than the control group, and there were also significant differences between the pneumonia group and pneumonia-derived sepsis group (p < .001), and there was association between lower serum 25(OH)D level and more serious symptoms. 23 Daneshkhah et al. 24 observed that high C-reactive protein (CRP) was inversely correlated with 25(OH)D, and they thought vitamin D to have a possible role in reduction of complications caused by abnormal inflammation and cytokine storm given the CRP as a marker for cytokine storm and considering its association with vitamin D deficiency. Some previous studies found negative correlation between 25(OH) D vitamin level and pneumonia severity, CRP level, increased risk of sepsis, ARDS risk and increased production of proinflammatory cytokines, such as IL-6. [25] [26] [27] [28] [29] In a study conducted by Alipio et al. 30 evaluation of the association between vitamin D with clinical and laboratory findings of the disease and its effect on mortality. This study received no specific grant from any funding agency in the public, commercial, or not for profit sectors. The author declares that there are no conflict of interests. Kamil Yılmaz and Velat Şen wrote the manuscript. All authors read and approved the final manuscript. Kamil Yılmaz https://orcid.org/0000-0001-5137-0501 Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): rationale and feasibility of a shared pragmatic protocol Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020 Coronavirus disease 2019 (COVID-19) in Italy Epidemiology of COVID-19 Among Children in China Coronavirus disease 2019 in children -United States Does vitamin D status impact mortality from SARS-CoV-2 infection? Medicine in drug discovery SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Angiotensin-converting enzyme 2 as the molecular bridge between epidemiologic and clinical features of COVID-19 25-Dihydroxy-3-epi-vitamin D3, a natural metabolite of 1α, 25-dihydroxy vitamin D3: production and biological activity studies in pulmonary alveolar type II cells Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system Optimisation of vitamin D status for enhanced immuno-protection against COVID-19 Vitamin D and respiratory health Vitamin D effects on lung immunity and respiratory diseases Preventive effects of vitamin D on seasonal influenza A in infants: a multicenter, randomized, open, controlled clinical trial Effect of high-dose vs standard-dose wintertime vitamin d supplementation on viral upper respiratory tract infections in young healthy children Modulation of the immune response to respiratory viruses by vitamin D Vitamin D status across age groups in Turkey: results of 108742 samples from a private laboratory Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement Causes of childhood deaths in Bangladesh: results of a nationwide verbal autopsy study Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data Association between serum 25-hydroxyvitamin D concentration and pulmonary infection in children The role of vitamin D in suppressing cytokine storm in COVID-19 patients and associated mortality. medRxiv Link between community-acquired pneumonia and vitamin D levels in older patients The association between vitamin D deficiency and community-acquired pneumonia: A meta-analysis of observational studies Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons Study of IL-6 and vitamin D3 in patients of pulmonary tuberculosis Serum 25-hydroxyvitamin d levels and C-reactive protein in persons with human immunodeficiency virus infection Vitamin D supplementation could possibly improve clinical outcomes of patients infected with coronavirus-2019 (COVID-19). Available at SSRN 3571484 Vitamin D insufficiency is prevalent in severe COVID-19. medRxiv Patterns of COVID-19 mortality and vitamin D: an Indonesian study Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities? The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality